Earle Chiles Research Institute

ST. PAUL, Minn., Oct. 8, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Eric Tran, Ph.D, Associate Member of the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, has been awarded a G-Rex Grant. Dr. Tran's $200,000 G-Rex Grant will enable process development and IND enabling studies of a novel KRAS-targeted TCR-T cell therapy. "We have utilized G-Rex devices for a long time for our adoptive cell therapy efforts. This G-Rex Grant will substantially defray the costs associated with bringing our next generation TCR-T cell therapy into the clinic and advance the state of our manufacturing," said Dr. Tran "Dr. Tran has been contributing to the field of cell and gene therapy for nearly 15 years and we are grateful for the opportunity to award a G-Rex Grant to Dr. Tran and the Providence Cancer Institute. Providence's G-Rex Grant will help expedite an IND application of their novel KRAS-targeted TCR T-cell therapy to treat a variety of solid tumors in a Phase 1/1b clinical trial," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of the G-Rex Grant, Dr. Tran plans to optimize their manufacturing process by reducing the process duration and implementing fully-closed system G-Rex bioreactors. Dr. Tran will make use of Bio-Techne's new GMP cytokines that have been right-sized for one-touch G-Rex close process manufacturing, setting the stage for simple and efficient scale out. ScaleReady's G-Rex® Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ScaleReady ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact [email protected]. About Wilson Wolf Manufacturing Wilson Wolf () is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Providence Cancer Institute of Oregon Providence Cancer Institute of Oregon, a part of Providence St. Joseph Health, offers the latest in cancer services, including diagnosis, treatment, prevention, education and support. Providence is home to the Earle A. Chiles Research Institute, an internationally renowned leader in the field of cancer immunotherapy since 1993, where investigators lead numerous clinical trials for patients with cancers of the breast, colon, prostate, lung, esophagus, liver, pancreas, head and neck, ovary, skin, blood and other conditions. Learn more at Providence.org/ORcancer. SOURCE Bio-Techne Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

HST-1011 showed an encouraging early clinical profile demonstrating important linkages between exposure, target engagement, pharmacodynamics and initial signs of clinical activity, along with a generally manageable safety profile, in heavily pre-treated patients with advanced solid tumors Data represent the most comprehensive disclosure of clinical experience with a CBL-B inhibitor to date BOSTON, Sept. 12, 2024 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of initial clinical data for HST-1011, an investigational oral, selective inhibitor of Casitas B-lineage lymphoma proto-oncogene (CBL-B). Data from the Phase 1 monotherapy dose escalation portion of the study are being shared in a proffered oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. "These initial data provide the first comprehensive insight into the clinical experience with a CBL-B inhibitor, a novel immuno-oncology mechanism with the potential to meaningfully transform the treatment paradigm for patients with solid tumors," said Timothy Reilly, Ph.D., Chief Development Officer of HotSpot. "Critically, HST-1011 demonstrated important linkages between drug exposures, target engagement, and proximal and distal measures of pharmacology, and we observed initial signs of clinical benefit, in a heavily pre-treated, advanced solid tumor patient population. We believe these data provide a strong foundation for the continued evaluation of HST-1011 in dedicated patient populations and for the further assessment of HST-1011 in combination with a PD-1 inhibitor, cemiplimab." The Phase 1/2 study of HST-1011 (NCT05662397) is an open-label clinical study designed to evaluate HST-1011 alone and subsequently in combination with Regeneron's anti-PD-1 therapy, Libtayo® (cemiplimab), in adult patients with advanced solid tumors that are relapsed on or are refractory to anti-PD(L)-1 or standard of care therapies. The results being presented at ESMO include data from 28 patients in the monotherapy dose escalation portion of the study. The presentation describes the following data: Patients had a diverse range of solid tumor types and were heavily pre-treated, with a median of four prior lines of therapy, including 89% who had been treated previously with immunotherapy. HST-1011 was generally well tolerated across a range of twice-weekly doses, with no dose-limiting toxicities. The most frequent adverse events were gastrointestinal in nature, which were generally mitigated by the adoption of a prophylactic pre-treatment regimen. Encouraging linkages were observed between pharmacokinetics (PK), target engagement, pharmacodynamics (PD) and initial signals of clinical activity. Despite the heavily pre-treated, advanced cancer patient population, indications of clinical benefit, including tumor stasis or shrinkage, were observed in 10 of the 28 patients across a range of tumor types and dose levels. These encouraging data provide support for the ongoing evaluation of HST-1011 (NCT05662397). Presentation details are as follows: Title: First-in-Human (FIH) Phase 1 Data of HST-1011, an Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors Speaker: Rachel E. Sanborn, M.D., Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR Session Name: Proffered Paper session: Investigational immunotherapy Session Date and Time: Fri., Sep. 13, 2024, 16:00-17:30 CEST Presentation Time: 16:50-17:00 CEST Location: Burgos Auditorium – Hall 5, Fira Barcelona Gran Via Presentation Number: 991O About HotSpot Therapeutics, Inc. HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company's proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of cancer and autoimmune diseases. To learn more, visit . Investor & Media Contact: Natalie Wildenradt [email protected] SOURCE HotSpot Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Eighteen early-career clinical investigators to receive year-long mentorship through professional development program led by international thought leaders ATLANTA, June 10, 2024 /PRNewswire/ -- Bio Ascend, Vaniam Group's medical education company, recently convened its Academy of Next Wave of Investigators™. These young clinical investigators will all receive a year-long opportunity to engage in live and virtual career development seminars with international thought leaders caring for patients with lung cancer. "These already-accomplished, early-career investigators will receive invaluable guidance from the Next Wave™ faculty, springboarding their continued success toward becoming the next generation of leaders in the field of thoracic oncology," said Kraig Steubing, Head of Bio Ascend and Senior Vice President of Strategic Engagement at Vaniam Group. "We are honored to partner with our distinguished faculty in providing the investigators with intensive mentorship across a wide range of topics—spanning research, grant applications, presentation skills, career development, and leadership—to ensure patients diagnosed with lung cancer receive expert care now, and for decades to come." The 2024-2025 class convened for a 2-day conference on May 10th and 11th in Atlanta, where the esteemed faculty shared lessons on how the inaugural class can enhance their research and expand their impact on the future of patient care. Following this meeting, the early-career investigators will meet regularly with their assigned mentors, and the entire class will reconvene at a networking reception at the American Society of Clinical Oncology Annual Meeting in 2025. "The Next Wave™ Forum kickoff meeting provided an opportunity to meet with colleagues and mentors from around the country, hone presentation skills, and get feedback on our ideas from seasoned investigators. I'm excited for the year ahead working with and learning from this wonderful group," said Dr. Susan Scott, a Next Wave™ young investigator and Assistant Professor of Oncology at the Johns Hopkins University School of Medicine. The Academy's faculty of accomplished thought leaders, who also serve as mentors for the Next Wave of Investigators™ throughout 2024-2025, include: (Co-Chair) Julie Brahmer, MD, MSc, Marilyn Meyerhoff Professor in Thoracic Oncology, Director, Thoracic Oncology Program, Codirector, Cancer Immunology Program, Codirector, Upper Aerodigestive Department, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Medicine (Co-Chair) Suresh Ramalingam, MD, FACP, FASCO, Professor, Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology/Oncology, Emory University School of Medicine, Assistant Vice President for Cancer, Woodruff Health Sciences Center, Executive Director, Winship Cancer Institute of Emory University Tina Cascone, MD, PhD, Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Shirish Gadgeel, MD, Professor, Head, Division of Hematology/Oncology, Associate Director, Patient Experience and Clinical Care, Department of Internal Medicine, Henry Ford Hospital, Wayne State University School of Medicine Ramaswamy Govindan, MD, Professor, Anheuser Busch Endowed Chair in Medical Oncology, Director, Section of Medical Oncology, Associate Chief, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine in St. Louis Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, Associate Director, Division of Medical Oncology, Consultant Hematologist and Medical Oncologist, Multi-D Oncology Clinic, Indiana University Health, Indiana University School of Medicine Mark Kris, MD, Professor, Weill Cornell Medicine, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center Natasha Leighl, MD, MMSc, PhD, FRCP, FASCO, Professor, University of Toronto, Lung Site Lead, Consultant Thoracic Oncologist, Princess Margaret Cancer Centre Rachel Sanborn, MD, Medical Director, Thoracic Oncology Program, Medical Director, Phase I Clinical Trials Program, Earle A. Chiles Research Institute, Providence Cancer Institute Lecia Sequist, MD, MPH, Landry Family Professor of Medicine, Harvard Medical School, Program Director, Cancer Early Detection and Diagnostics Clinic, Consultant Thoracic Oncologist, Massachusetts General Hospital The Next Wave™ young investigators, each nominated by their fellowship directors or thought leaders, include: Fatemeh Ardeshir-Larijani, MD, MSc, Assistant Professor of Medicine, Winship Cancer Institute of Emory University Christine Auberle, MD, Chief Clinical Research Fellow, Washington University School of Medicine in St. Louis Ayse Ece Cali Daylan, MD, PhD, Chief Hematology/Oncology Fellow, Montefiore Medical Center Giordano Fabricio Cittolin-Santos, MD, PhD, Chief Hematology/Oncology Fellow, Barnes-Jewish Hospital, Washington University School of Medicine in St. Louis Alissa J. Cooper, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center Colum Dennehy, MBBCh, MSc, Clinical Fellow, Johns Hopkins Hospital Nadia Ghazali, MBBS, Clinical Research Fellow, Princess Margaret Cancer Centre Radhika Gutta, DO, Clinical Fellow, Henry Ford Hospital Sameena Khan, MBChB, MRes, PhD, MRCP, Clinical Research Fellow, Princess Margaret Cancer Centre June-Koo (Jake) Lee, MD, PhD, Clinical Fellow, Memorial Sloan Kettering Cancer Center Koosha Paydary, MD, MPH, MSc, Assistant Professor of Medicine, Rush University Medical Center Amanda Reyes, MD, MS, Clinical Research Fellow, City of Hope Ivy Riano Monsalve, MD, Instructor of Medicine, Geisel School of Medicine at Dartmouth, Chief Clinical Fellow, Dartmouth Cancer Center Susan Scott, MD, Assistant Professor of Medicine, Johns Hopkins School of Medicine Chetan Vakkalagadda, MD, Assistant Professor of Medicine, Oregon Health & Science University Victoria E. Wang, MD, PhD, Assistant Professor of Medicine, University of California San Francisco Health Yating Wang, MD, Clinical Instructor, Michigan State University School of Medicine Urs Michael Weber, MD, Clinical Fellow, University of Colorado School of Medicine Future classes of the Academy of Next Wave of Investigators™ are planned for young investigators specializing in hematologic malignancies, gynecologic cancers, and thoracic oncology. About Bio Ascend Part of Vaniam Group, Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice. The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians. For more information, visit . About Vaniam Group Vaniam Group is a people-first, purpose-driven, independent network of healthcare and scientific communications agencies committed to helping biopharmaceutical companies realize the full potential of their compounds across oncology, virology, and rare disease. Founded in 2007 as a virtual-by-design organization, Vaniam Group harnesses the talents and expertise of team members around the world. For more information, visit . SOURCE Vaniam Group LLC